Telos Capital Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.3M Buy
84,626
+1,815
+2% +$161K 0.64% 52
2026
Q2
$7.49M Buy
82,811
+396
+0.5% +$33.2K 0.66% 51
2026
Q1
$6.6M Buy
82,415
+4,700
+6% +$387K 0.63% 65
2025
Q4
$6.63M Buy
77,715
+5,630
+8% +$462K 0.62% 60
2025
Q3
$5.61M Buy
72,085
+9,670
+15% +$756K 0.54% 72
2025
Q2
$4.88M Buy
62,415
+7,156
+13% +$534K 0.5% 76
2025
Q1
$4.01M Buy
55,259
+3,665
+7% +$262K 0.44% 80
2024
Q4
$3.82M Sell
51,594
-47,300
-48% -$3.31M 0.41% 80
2024
Q3
$6.53M Buy
98,894
+1,519
+2% +$110K 0.68% 56
2024
Q2
$8.99M Buy
97,375
+2,045
+2% +$181K 1% 33
2024
Q1
$9.11M Buy
95,330
+3,925
+4% +$330K 1.03% 33
2023
Q4
$6.97M Buy
91,405
+56,000
+158% +$3.9M 0.85% 38
2023
Q3
$2.45M Buy
35,405
+4,555
+15% +$366K 0.34% 79
2023
Q2
$2.91M Buy
+30,850
New +$2.68M 0.39% 74

Other funds holding EW

Telos Capital Management's EW Position: Q3 2026 in Review

Telos Capital Management increased its Edwards Lifesciences (EW) stake by 2.2% in Q3 2026, buying an estimated $161K and bringing the position to 84,626 shares worth $7.3M. The position accounts for 0.64% of the portfolio, ranked #52.

Telos Capital Management first reported a position in EW in Q2 2023 and has held it in 14 quarters since. The position peaked at $9.11M in Q1 2024. 1,342 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Telos Capital Management held 84,626 shares of Edwards Lifesciences worth $7.3M as of Q3 2026.
  • Telos Capital Management bought 1,815 Edwards Lifesciences shares in Q3 2026, an estimated $161K.
  • Edwards Lifesciences made up 0.64% of Telos Capital Management's portfolio in Q3 2026, its #52 holding.
  • Telos Capital Management first reported a position in Edwards Lifesciences in Q2 2023 and has held it in 14 quarters since.
  • Telos Capital Management's Edwards Lifesciences position peaked at $9.11M in Q1 2024.
  • 1,342 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Telos Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.